IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PECORELLI, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.687
EU - Europa 3.921
AS - Asia 2.566
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 11
SA - Sud America 10
Totale 18.233
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.631
CN - Cina 1.427
UA - Ucraina 1.288
IT - Italia 605
DE - Germania 532
SG - Singapore 463
PL - Polonia 394
FI - Finlandia 355
HK - Hong Kong 330
IE - Irlanda 192
TR - Turchia 180
GB - Regno Unito 162
RU - Federazione Russa 155
IN - India 104
FR - Francia 98
SE - Svezia 57
CA - Canada 51
EE - Estonia 23
BE - Belgio 18
MU - Mauritius 18
NL - Olanda 18
EU - Europa 16
VN - Vietnam 16
AU - Australia 11
IR - Iran 9
ID - Indonesia 8
BR - Brasile 7
CZ - Repubblica Ceca 6
LT - Lituania 6
KR - Corea 5
TW - Taiwan 4
BG - Bulgaria 3
CH - Svizzera 3
MX - Messico 3
CL - Cile 2
IQ - Iraq 2
JP - Giappone 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
EG - Egitto 1
ES - Italia 1
IL - Israele 1
JO - Giordania 1
MA - Marocco 1
MS - Montserrat 1
NG - Nigeria 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 18.233
Salva come PNG Salva come JPEG
Città #
Fairfield 1.662
Woodbridge 1.636
Houston 1.108
Jacksonville 914
Ashburn 900
Ann Arbor 800
Wilmington 761
Seattle 695
Cambridge 644
Warsaw 393
Singapore 367
Chandler 364
Nanjing 353
Princeton 353
Hong Kong 312
New York 218
Dearborn 212
Dublin 192
Beijing 181
Helsinki 169
Istanbul 157
Nanchang 128
Moscow 99
San Diego 90
Shenyang 87
Des Moines 86
Changsha 67
Hebei 67
Kunming 66
Milan 65
Shanghai 65
Jiaxing 58
Jinan 57
Tianjin 48
Los Angeles 47
Toronto 45
Brescia 43
Hangzhou 41
London 28
Ningbo 25
Tallinn 23
Zhengzhou 23
Verona 22
Monmouth Junction 20
Rome 19
Brussels 18
Lancaster 18
Lanzhou 18
Taizhou 18
Hefei 17
Washington 17
Dong Ket 16
Norwalk 16
Orange 16
Pune 16
Central 14
San Francisco 14
Taiyuan 12
Guangzhou 11
Fuzhou 10
Munich 10
Ardabil 9
Falkenstein 9
Haikou 9
Kocaeli 9
Leawood 8
Kilburn 7
New Bedfont 7
San Mateo 7
Boardman 6
Changchun 6
Melbourne 6
Amsterdam 5
Chicago 5
Dalmine 5
Jakarta 5
Phoenix 5
Augusta 4
Hanover 4
Indiana 4
Lappeenranta 4
Prezzo 4
Southwark 4
São Paulo 4
Trani 4
Arezzo 3
Auburn Hills 3
Bologna 3
Brno 3
Chiari 3
Chongqing 3
Frankfurt am Main 3
Kaunas 3
Mexico City 3
Newark 3
North 3
Ottawa 3
Romola 3
Santa Clara 3
Santuario 3
Totale 14.136
Salva come PNG Salva come JPEG
Nome #
Bambini pretermine: nati per vivere 288
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 268
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 260
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. 258
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 228
OVEREXPRESSION OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTORS CLAUDIN-3 AND CLAUDIN-4 IN UTERINE CARCINOSARCOMAS. 184
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 160
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 153
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 149
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 145
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women 144
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 143
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 141
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). 141
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 141
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). 140
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 140
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin 138
Consolidation therapies revisited: weekly paclitaxel 136
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 136
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. 133
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 132
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 131
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 131
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 130
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 129
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas 129
Carcinoma of the Fallopian tube 129
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 125
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 125
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 123
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 121
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 120
Chlamydia trachomatis genotypes in school adolescents, Italy 120
Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board 120
Mammaglobin B expression in human endometrial cancer 119
ADVANCES IN DENDRITIC-CELL-BASED THERAPEUTIC VACCINES FOR CERVICAL CANCER. 118
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 118
Mental health and the global agenda. 117
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 117
Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight 116
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 116
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 115
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. 114
Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency 114
Gestational trophoblastic diseases 114
Replacement therapy for breast cancer survivors. A pilot study 114
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 113
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 112
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 112
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. 111
Revised FIGO staging for carcinoma of the vulva, cervix, andendometrium. 111
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody 111
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model 111
Carcinoma of the Fallopian tube 110
Toward appropriate criteria in medication adherence assessment in older persons: Position Paper 110
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 110
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. 109
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 109
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS) 107
Prescription drug use among older adults in Italy: A country-wide perspective 107
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 106
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA) 106
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor 106
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer 105
Early stage cervical cancer: adjuvant treatment in negative lymph node cases. 105
Scaling up health knowledge at European level requires sharing integrated data: An approach for collection of database specification 105
History of the FIGO cancer staging system 104
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 104
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 103
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 103
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 102
New development of the FIGO staging system. 102
Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in Uterine Serous Papillary Cancer 102
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 102
Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy 101
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 101
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? 101
Early stage ovarian cancer: the Italian contribution to clinical research. An update 101
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. 100
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. 100
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor 100
Hearing loss and cognitive decline in older adults: Questions and answers 100
hI-con1, a factor VII-IgGFc chimeric protein targetingtissue factor for immunotherapy of uterine serous papillary carcinoma. 99
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. 99
Hormone replacement therapy in breast cancer 99
Interval debulking surgery in advanced epithelial ovarian cancer 98
Gestational trophoblastic diseases 98
Optimizing gemcitabine regimens in ovarian cancer. 97
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 97
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 97
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) 97
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 96
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES COMPARED WITH TUMOR-ASSOCIATED LYMPHOCYTES FROM ASCITIC FLUID AND PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH ADVANCED OVARIAN CANCER. 96
Revised FIGO staging for carcinoma of the cervix. 96
The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervicalcancer cells. 95
Carcinoma of the corpus uteri 95
Radiation-Enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma 93
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. 93
THE NOVEL SERINE PROTEASE TUMOR-ASSOCIATED DIFFERENTIALLY EXPRESSED GENE-14 (KLK8/NEUROPSIN/OVASIN) IS HIGHLY OVEREXPRESSED IN CERVICAL CANCER. 93
Totale 12.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.765
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.765
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.134 0 0 0 0 0 744 523 547 370 566 110 274
2020/20212.785 64 363 116 345 126 334 135 323 360 263 271 85
2021/20221.537 124 236 13 71 11 106 77 88 77 292 123 319
2022/20231.190 240 30 50 69 83 343 10 94 153 11 52 55
2023/20241.512 78 35 145 108 82 358 49 60 330 57 20 190
2024/2025993 19 31 10 379 308 246 0 0 0 0 0 0
Totale 18.674